facebooktwittertelegramwhatsapp
copy short urlprintemail
+ A
A -
webmaster
AS the prevalence of diabetes reaches alarming proportions across the world, Dr Alexandra Butler, principal investigator at Qatar Biomedical Research Institute, part of Hamad Bin Khalifa University, talks about the efforts being made by Qatar to tackle the disease.
What is diabetes?
Diabetes is a disease that occurs when there is an inability to produce adequate amounts of insulin to maintain blood glucose levels within normal limits, and it represents a major medical, social, and economic burden worldwide. The prevalence of diabetes has reached epidemic proportions globally, with 424.9 million affected adults aged 20-79, representing 8.8 percent of the global adult population.
This figure is predicted to rise to 628.6 million by 2045, affecting almost 10 percent of the worldwide adult population. Type 2 diabetes accounts for 90 to 95 percent of diabetes cases, with type 1 diabetes accounting for about 5 percent. However, half of those with type 2 diabetes have not been diagnosed. In Qatar, 20 percent of the population is affected by diabetes (type 2 accounting for 90 percent of those) with a projected rise to 24 percent in the next two decades. Diabetes in Qatar affects all segments of society, from the young to the elderly, and places a significant social and economic burden on Qatari society.
What is the difference between type 1 and type 2 diabetes, and are there other types?
The reasons underlying the inability to produce adequate amounts of insulin depend upon the type of diabetes. Type 1 is essentially a total insulin deficiency due to the destruction of beta cells by the body’s immune system. Type 2 is a complex disease characterised by insulin resistance and insulin deficiency.The degrees of resistance and deficiency vary, but insulin deficiency is key to developing diabetes.
Gestational diabetes is a form of diabetes that can develop during pregnancy as pregnancy is a state of increased insulin resistance and these women have a higher risk of developing type 2 diabetes later in life. There are also genetic defects of beta cell function and insulin action, such as Maturity Onset Diabetes of the Young (MODY). Some conditions, such as diseases of the exocrine pancreas, can cause secondary diabetes as can certain drugs, corticosteroids being a prime example.
What are the symptoms of diabetes?
Those with type 1 diabetes may experience thirst, a frequent need to urinate, weight loss, fatigue, blurred vision, ketoacidosis (a life-threatening conditions where the body starts breaking down fat at a rapid rate), and infections.
Type 2 diabetes can lead to thirst, frequent urination, and malaise, but symptoms are usually much milder and many individuals with type 2 diabetes do not know they have the disease until they are tested. In certain circumstances, it can be difficult to distinguish between type 1 and type 2 diabetes (see Table 1). Distinguishing the type of diabetes can be particularly difficult in younger patients who are treated with insulin, but clinically appear to have type 2 diabetes, and older patients with late onset of diabetes who require insulin and share characteristics of patients with type 1 diabetes where Latent Autoimmune Diabetes of Adulthood (LADA) should be considered.
What role is QBRI playing in relation to diabetes research?
The genetic risks for type 2 diabetes are likely to be different for Qataris compared to other Asians and Europeans. Therefore, identification of factors that are associated with the high prevalence of type 2 diabetes in the Qatari population is an important focus of ongoing research at the Diabetes Research Center (DRC) at QBRI.
Diabetic complications are costly, extremely difficult to manage, and lead to increased mortality rates. Diabetics are also at increased risk of neurological impairment and certain forms of cancer, so identifying biomarkers that predict the future development of diabetes and/or its related complications is imperative.
Accordingly, biomarker discovery is a major focus of the ongoing research at the DRC. With the advent of stem cells, the concept of mimicking nature to generate new beta-cells to reverse diabetes has emerged, although more work needs to be done to allow for safe and effective therapy.
In collaboration with the Harvard Stem Cell Institute, the Stem Cell group at DRC is working towards developing safe and effective stem cell-derived therapy to meet the needs of diabetic patients in Qatar.
copy short url   Copy
15/11/2019
486